A placebo-controlled trial of astaxanthin in subjects with nonalcoholic fatty liver disease

A placebo-controlled trial of astaxanthin in subjects with nonalcoholic fatty liver disease - AX-NAFLD-1

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008524

Enrollment

Registered

2012-07-24

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease (NAFLD)

Interventions

Astaxanthin 12mg daily for 6 months Placebo for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who 1) are 18 and older at time fo consent, male of female 2) are histologically diagnosed as NAFLD by liver biopsy 3) have ALT 30 and higher 4) have alcohol intake 30 gram and less for male, and 20 gram and less for female

Exclusion criteria

Exclusion criteria: Subjects who 1) are infected with HBV or HCV 2) have alcohol intake more than 30 for male, and more than 20 gram for female 3) have malignant tumor including hepatocellular carcinoma

Design outcomes

Primary

Measure	Time frame
Serum alanine aminotransferase level	—

Secondary

Measure	Time frame
Histologic features of nonalcoholic steatohepatitis	—

Countries

Japan

Contacts

Public ContactTsuguhito Ota

Kanazawa University Department of Medicine

076-2665-2234

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026